Page last updated: 2024-09-03

n-acetyllactosamine and Pleural Effusion, Malignant

n-acetyllactosamine has been researched along with Pleural Effusion, Malignant in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carrasco, J; Courtoy, PJ; Demotte, N; Lurquin, C; Moser, M; Schmidt, C; Squifflet, JL; Thielemans, K; van der Bruggen, P; Van Der Smissen, P; Weynand, B; Wieƫrs, G1

Other Studies

1 other study(ies) available for n-acetyllactosamine and Pleural Effusion, Malignant

ArticleYear
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
    Cancer research, 2010, Oct-01, Volume: 70, Issue:19

    Topics: Amino Sugars; Animals; Ascites; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Galectin 3; Humans; Interferon-gamma; Ligands; Lymphocytes, Tumor-Infiltrating; Mastocytoma; Melanoma; Mice; Neoplasms; Pleural Effusion, Malignant; Polysaccharides; Receptors, Antigen, T-Cell

2010